In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three ... Overall, we are quite pleased with Regeneron Pharmaceuticals' performance. In particular, it's great to see ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance.

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

In 2021, Regeneron earned $5.8bn ... relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

But this hasn't helped share performance over the past year. The stock has slipped over that ... The FDA authorized Regeneron's antibody cocktail for mild-to-moderate COVID-19 cases in high ...